Exact Sciences Releases 4Q Stats
Exact Sciences recently announced its fourth quarter numbers, which included revenues between $34.9 million – $35.4 million and 82,000 completed Cologuard tests, an increase of 142 percent and 114 percent…
Category Archives: Biotech
2017 BioForward Board Announced
Five new members were voted onto the BioForward board of directors, the organization announced today. Serving a 2017-19 term from Madison are Exact Sciences CIO Gary Frings and HealthMyne Chief Strategy…
SHINE Lands $20.9M Agreement
SHINE Medical Technologies has been awarded $10 million from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) as part of a $20.9 million cooperative agreement, the company announced…
Cellectar Biosciences Receives Patent
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as…
Cologuard Offered to Humana Members
Beginning Jan. 1, Exact Sciences’ Cologuard will be included for Humana members, the company announced today. Humana has nearly 10 million beneficiaries and is the nation’s fifth largest commercial insurer. “As demand…
PhylloTech Nabs SBIR Grant
PhylloTech, a biopesticide developer and plant biotechnology company, announced today that it is the recipient of the second phase of a National Science Foundation SBIR contract worth $750,000. According to a…
Cellectar Sees Benefits in Study
Cellectar Biosciences announced recently a clinical benefit rate of 80 percent from its Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. “The efficacy…
Propeller, MIR to Collaborate
Propeller Health announced today that it will collaborate with Medical International Research (MIR), a global leader in spirometry, oximetry and telemedicine, to integrate several of MIR’s mobile and clinical spirometers into the…
OnLume Earns $300K SBIR Grant
OnLume, a medical device company developing surgical lighting technology, is the recipient of a Phase I SBIR grant through the National Cancer Institute SBIR worth $300,000. “At OnLume, we believe…
Cellectar Makes $8M Public Offering
Cellectar Biosciences today announced the effective price of $1.50 per share of common stock of an underwritten public offering to raise approximately $8 million. According to a release, Cellectar will use…
